Recent Updates
Recently added Catalysts

Sorivudine

Phase 3

HIV Infections | Small molecule | Infectious Disease |Bristol-Myers Squibb Company|Last Updated: Mar 1, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials2
Total Enrollment180
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00002358A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZVPHASE3 COMPLETED - - -Oct 2, 20071 United States
NCT00000953Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected PatientsPHASE2 COMPLETED 180 - -Mar 1, 201144 United States
Unlock Drug Trial Details
Study Design & Arms
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
SorivudineDRUG -
AcyclovirDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range2 Years — 17 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria Patients must have: * HIV infection. * Cutaneous, visceral, or ocular varicella-zoster viral infection. * Refractory or intolerant to acyclovir or foscarnet therapy. * Consent of parent or guardian. Exclusion Criteria Co-existing Condition: Patients with the following symptom...

Countries:United States
Unlock Eligibility Criteria